Dysferlinopathies are caused by mutations in the DYSF gene. Dysferlin is a protein mainly expressed in the skeletal muscle and monocytes. Cell therapy constitutes a promising tool for the treatment of muscular dystrophies. The aim of our study was to evaluate the effect of bone marrow transplantation (BMT) using the A/J Dysfprmd mouse model of dysferlinopathy. For that purpose, we studied dysferlin expression by western blot and/or immunohistochemistry in transplanted mice and controls. Computerized analyses of locomotion and electrophysiological techniques were also performed to test the functional improvement. We observed dysferlin expression in splenocytes, but not in the skeletal muscle of the transplanted mice. However, the locomotion test, electromyography studies, and muscle histology showed an improvement in all transplanted mice that was more significant in the animals transplanted with dysferlin+/+ cells. In conclusion, although BMT restores dysferlin expression in monocytes, but not in skeletal muscle, muscle function was partially recovered. We propose that the slight improvement observed in the functional studies could be related with factors, such as the hepatocyte growth factor, released after BMT that prevented muscle degeneration.
Get full access to this article
View all access options for this article.
References
1.
LiuJ, AokiM, IllaI, WuC, FardeauM, AngeliniC, SerranoC, UrtizbereaJA, HentatiFet al.1998. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet, 20:31–36.
2.
BashirR, BrittonS, StrachanT, KeersS, VafiadakiE, LakoM, RichardI, MarchandS, BourgNet al.1998. A gene related to Caenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B. Nat Genet, 20:37–42.
3.
IllaI, De LunaN, Dominguez-PerlesR, Rojas-GarciaR, ParadasC, PalmerJ, MarquezC, GallanoP, GallardoE. 2007. Symptomatic dysferlin gene mutation carriers: characterization of two cases. Neurology, 68:1284–1289.
4.
IllaI, Serrano-MunueraC, GallardoE, LasaA, Rojas-GarciaR, PalmerJ, GallanoP, BaigetM, MatsudaC, BrownRH. 2001. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol, 49:130–134.
5.
NguyenK, BassezG, KrahnM, BernardR, LaforetP, LabelleV, UrtizbereaJA, Figarella-BrangerD, RomeroNet al.2007. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes. Arch Neurol, 64:1176–1182.
6.
ParadasC, Gonzalez-QueredaL, De LunaN, GallardoE, Garcia-ConsuegraI, GomezH, CabelloA, IllaI, GallanoP. 2009. A new phenotype of dysferlinopathy with congenital onset. Neuromuscul Disord, 19:21–25.
7.
Passos-BuenoMR, BashirR, MoreiraES, VainzofM, MarieSK, VasquezL, IughettiP, BakkerE, KeersS, StephensonAet al.1995. Confirmation of the 2p locus for the mild autosomal recessive limb-girdle muscular dystrophy gene (LGMD2B) in three families allows refinement of the candidate region. Genomics, 27:192–195.
8.
MiyoshiK, KawaiH, IwasaM, KusakaK, NishinoH. 1986. Autosomal recessive distal muscular dystrophy as a new type of progressive muscular dystrophy. Seventeen cases in eight families including an autopsied case. Brain, 109,Pt 1:31–54.
9.
BashirR, KeersS, StrachanT, Passos-BuenoR, ZatzM, WeissenbachJ, Le PaslierD, MeislerM, BushbyK. 1996. Genetic and physical mapping at the limb-girdle muscular dystrophy locus (LGMD2B) on chromosome 2p. Genomics, 33:46–52.
10.
ParadasC, LlaugerJ, Diaz-ManeraJ, Rojas-GarciaR, De LunaN, IturriagaC, MarquezC, UsonM, HankiewiczK, GallardoE, IllaI. 2010. Redefining dysferlinopathy phenotypes based on clinical findings and muscle imaging studies. Neurology, 75:316–323.
11.
GallardoE, Rojas-GarciaR, de LunaN, PouA, BrownRHJr., IllaI. 2001. Inflammation in dysferlin myopathy: immunohistochemical characterization of 13 patients. Neurology, 57:2136–2138.
12.
VandreDD, AckermanWE, KnissDA, TewariAK, MoriM, TakizawaT, RobinsonJM. 2007. Dysferlin is expressed in human placenta but does not associate with caveolin. Biol Reprod, 77:533–542.
13.
BansalD, CampbellKP. 2004. Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol, 14:206–213.
14.
De LunaN, FreixasA, GallanoP, CasellesL, Rojas-GarciaR, ParadasC, NogalesG, Dominguez-PerlesR, Gonzalez-QueredaLet al.2007. Dysferlin expression in monocytes: a source of mRNA for mutation analysis. Neuromuscul Disord, 17:69–76.
15.
HoM, GallardoE, McKenna-YasekD, De LunaN, IllaI, BrownRHJr.2002. A novel, blood-based diagnostic assay for limb girdle muscular dystrophy 2B and Miyoshi myopathy. Ann Neurol, 51:129–133.
16.
NagarajuK, RawatR, VeszelovszkyE, ThapliyalR, KesariA, SparksS, RabenN, PlotzP, HoffmanEP. 2008. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol, 172:774–785.
Diaz-ManeraJ, TouvierT, DellavalleA, TonlorenziR, TedescoFS, MessinaG, MeregalliM, NavarroC, PeraniLet al.2010. Partial dysferlin reconstitution by adult murine mesoangioblasts is sufficient for full functional recovery in a murine model of dysferlinopathy. Cell Death Dis, 1:e61.
19.
de LunaN, GallardoE, SorianoM, Dominguez-PerlesR, de la TorreC, Rojas-GarciaR, Garcia-VerdugoJM, IllaI. 2006. Absence of dysferlin alters myogenin expression and delays human muscle differentiation “in vitro.”J Biol Chem, 281:17092–17098.
20.
De la TorreC, IllaI, FaulknerG, SoriaL, Robles-CedenoR, Dominguez-PerlesR, De LunaN, GallardoE. 2009. Proteomics identification of differentially expressed proteins in the muscle of dysferlin myopathy patients. Proteomics Clin Appl, 3:486–497.
21.
ArahataK, EngelAG. 1984. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol, 16:193–208.
de MorreeA, FlixB, BagaricI, WangJ, van den BoogaardM, Grand MourselL, FrantsRR, IllaI, GallardoE, ToesR, van der MaarelSM. 2013. Dysferlin regulates cell adhesion in human monocytes. J Biol Chem, 288:14147–14157.
24.
BittnerRE, AndersonLV, BurkhardtE, BashirR, VafiadakiE, IvanovaS, RaffelsbergerT, MaerkI, HogerHet al.1999. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat Genet, 23:141–142.
25.
KongKY, RenJ, KrausM, FinklesteinSP, BrownRHJr.2004. Human umbilical cord blood cells differentiate into muscle in sjl muscular dystrophy mice. Stem Cells, 22:981–993.
26.
VieiraNM, BuenoCRJr., BrandaliseV, MoraesLV, ZucconiE, SeccoM, SuzukiMF, CamargoMMet al.2008. SJL dystrophic mice express a significant amount of human muscle proteins following systemic delivery of human adipose-derived stromal cells without immunosuppression. Stem Cells, 26:2391–2398.
27.
HoM, PostCM, DonahueLR, LidovHG, BronsonRT, GoolsbyH, WatkinsSC, CoxGA, BrownRHJr.2004. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet, 13:1999–2010.
28.
GussoniE, SoneokaY, StricklandCD, BuzneyEA, KhanMK, FlintAF, KunkelLM, MulliganRC. 1999. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature, 401:390–394.
29.
ChretienF, DreyfusPA, ChristovC, CaramelleP, LagrangeJL, ChazaudB, GherardiRK. 2005. In vivo fusion of circulating fluorescent cells with dystrophin-deficient myofibers results in extensive sarcoplasmic fluorescence expression but limited dystrophin sarcolemmal expression. Am J Pathol, 166:1741–1748.
30.
Salah-MohellibiN, MilletG, Andre-SchmutzI, DesforgesB, OlasoR, RoblotN, CourageotS, BensimonG, Cavazzana-CalvoM, MelkiJ. 2006. Bone marrow transplantation attenuates the myopathic phenotype of a muscular mouse model of spinal muscular atrophy. Stem Cells, 24:2723–2732.
31.
FerrariG, Cusella-De AngelisG, ColettaM, PaolucciE, StornaiuoloA, CossuG, MavilioF. 1998. Muscle regeneration by bone marrow-derived myogenic progenitors. Science, 279:1528–1530.
32.
TeradaN, HamazakiT, OkaM, HokiM, MastalerzDM, NakanoY, MeyerEM, MorelL, PetersenBE, ScottEW. 2002. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion. Nature, 416:542–545.
33.
FerrariG, MavilioF. 2002. Myogenic stem cells from the bone marrow: a therapeutic alternative for muscular dystrophy?Neuromuscul Disord, 12,Suppl. 1:S7–S10.
34.
WillenbringH, BaileyAS, FosterM, AkkariY, DorrellC, OlsonS, FinegoldM, FlemingWH, GrompeM. 2004. Myelomonocytic cells are sufficient for therapeutic cell fusion in liver. Nat Med, 10:744–748.
35.
PuigT, KadarE, LimonA, CancelasJA, EixarchH, LuquinL, GarciaM, BarquineroJ. 2002. Myeloablation enhances engraftment of transduced murine hematopoietic cells, but does not influence long-term expression of the transgene. Gene Ther, 9:1472–1479.
36.
MatsudaR, YoshikawaM, KimuraH, OujiY, NakaseH, NishimuraF, NonakaJ, ToriumiH, YamadaSet al.2009. Cotransplantation of mouse embryonic stem cells and bone marrow stromal cells following spinal cord injury suppresses tumor development. Cell Transplant, 18:39–54.
37.
MancusoR, Santos-NogueiraE, OstaR, NavarroX. 2011. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol, 122:1660–1670.
38.
HamptonTG, StaskoMR, KaleA, AmendeI, CostaAC. 2004. Gait dynamics in trisomic mice: quantitative neurological traits of Down syndrome. Physiol Behav, 82:381–389.
39.
AmendeI, KaleA, McCueS, GlazierS, MorganJP, HamptonTG. 2005. Gait dynamics in mouse models of Parkinson's disease and Huntington's disease. J Neuroeng Rehabil, 2:20.
40.
MancusoR, OlivanS, OstaR, NavarroX. 2011. Evolution of gait abnormalities in SOD1(G93A) transgenic mice. Brain Res, 1406:65–73.
41.
GordonT, ThomasCK, MunsonJB, SteinRB. 2004. The resilience of the size principle in the organization of motor unit properties in normal and reinnervated adult skeletal muscles. Can J Physiol Pharmacol, 82:645–661.
42.
NicholsonLV, DavisonK, FalkousG, HarwoodC, O'DonnellE, SlaterCR, HarrisJB. 1989. Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. J Neurol Sci, 94:125–136.
43.
VillaltaSA, NguyenHX, DengB, GotohT, TidballJG. 2009. Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet, 18:482–496.
MancusoR, OlivanS, RandoA, CasasC, OstaR, NavarroX. 2012. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics, 9:814–826.
46.
HanJJ, CarterGT, RaJJ, AbreschRT, ChamberlainJS, RobinsonLR. 2006. Electromyographic studies in mdx and wild-type C57 mice. Muscle Nerve, 33:208–214.
47.
LostalW, BartoliM, RoudautC, BourgN, KrahnM, PryadkinaM, BorelP, SuelL, RocheJAet al.2012. Lack of correlation between outcomes of membrane repair assay and correction of dystrophic changes in experimental therapeutic strategy in dysferlinopathy. PLoS One, 7:e38036.
48.
PastorD, Viso-LeonM, Botella-LopezA, Jaramillo-MerchanJ, MoraledaJM, JonesJ, MartinezS. 2013. Bone marrow transplantation in hindlimb muscles of motoneuron degenerative mice reduces neuronal death and improves motor function. Stem Cells Dev, 22:1633–1644.
49.
MillayDP, MailletM, RocheJA, SargentMAet al.2009. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol, 175:1817–1823.
50.
HanR, FrettEM, LevyJR, RaderEP, LueckJD, BansalD, MooreSA, NgR, Beltran-Valero de BernabeD, FaulknerJA, CampbellKP. 2010. Genetic ablation of complement C3 attenuates muscle pathology in dysferlin-deficient mice. J Clin Invest, 120:4366–4374.
51.
ArnoldL, HenryA, PoronF, Baba-AmerY, van RooijenN, PlonquetA, GherardiRK, ChazaudB. 2007. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med, 204:1057–1069.
52.
KastnerS, EliasMC, RiveraAJ, Yablonka-ReuveniZ. 2000. Gene expression patterns of the fibroblast growth factors and their receptors during myogenesis of rat satellite cells. J Histochem Cytochem, 48:1079–1096.
53.
SheehanSM, TatsumiR, Temm-GroveCJ, AllenRE. 2000. HGF is an autocrine growth factor for skeletal muscle satellite cells in vitro. Muscle Nerve, 23:239–245.
54.
CornelisonDD, FillaMS, StanleyHM, RapraegerAC, OlwinBB. 2001. Syndecan-3 and syndecan-4 specifically mark skeletal muscle satellite cells and are implicated in satellite cell maintenance and muscle regeneration. Dev Biol, 239:79–94.
55.
TatsumiR, AllenRE. 2004. Active hepatocyte growth factor is present in skeletal muscle extracellular matrix. Muscle Nerve, 30:654–658.
Duran-StruuckR, DyskoRC. 2009. Principles of bone marrow transplantation (BMT): providing optimal veterinary and husbandry care of irradiated mice in BMT studies. J Am Assoc Lab Anim, 48:11–22.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
